Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06200597 · ClinicalTrials.gov registry record · Phase 1
A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects
A Phase 1 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT06200597 is a Phase 1 study that has completed, run by Almirall, S.A.. The registered enrollment target is 92 participants.
The verdict
NCT06200597, a Phase 1 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple ascending doses of LAD603 in healthy adult participants in both Part 1 and 2.
Interventions
- OTHER Placebo
- DRUG LAD603
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2025-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06200597
The ClinicalTrials.gov registry entry for NCT06200597 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06200597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06200597 about?
NCT06200597 is a clinical study titled "A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects". The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple ascending doses of LAD603 in healthy adult participants in both Part 1 and 2.
What is the current status of trial NCT06200597?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2023-12-05. Estimated completion is 2025-05-29.
What interventions are being tested in trial NCT06200597?
The interventions under investigation include: Placebo (OTHER), LAD603 (DRUG).
Who is sponsoring clinical trial NCT06200597?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.